@JonasRieth

University of Tübingen | Immunology and Oncology

Joined July 2020
  • Tweets13
  • Following11
  • Followers12
We conducted a phase I #clinicaltrial with CoVac-1, our #peptide-based #COVID19 #vaccine candidate for induction of SARS-CoV-2 T cell immunity. Our observations support the presently ongoing phase II trial for patients with B cell/antibody deficiency. Here’s what we found:
Nature Portfolio
@NaturePortfolio23 Nov 2021
A peptide-based vaccine candidate, called CoVac-1, is shown to induce immunity against SARS-CoV-2 in a phase I clinical trial reported in @Nature. The vaccine candidate induces T cell immunity and could be helpful for people with immunodeficiencies. go.nature.com/30RVRao
1
12
3
26
Very proud that @JulianeWalz received this years best abstract award at the @dgho_eV for her presentation on our peptide-based #COVID19 #vaccine for patients affected by antibody shortage
6
16
Two exciting talks were held by our lab members @mroerden1 and Jens Bauer on #Covid_19 #tcell responses in #Cancer patients and a new fusion protein as potential immunotherapeutic target for the treatment of FLHCC at this years @dgho_eV meeting
4
9
Check out our latest preprint: This first comprehensive analysis of #SARS_CoV_2 immune responses in #cancer patients reports on the implications of impaired SARS-CoV-2 T cell responses for understanding pathophysiology and predicting severity of #COVID19 researchsquare.com/article/r…

Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients

Cancer patients, in particular patients with hematological malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4+ and CD8+ T cell responses...

researchsquare.com
5
7
Der Wissenschaftler der Uni Tübingen wird mit dem Landesforschungspreis 2020 ausgezeichnet, der mit 100.000 Euro dotiert ist. tagblatt.de/Nachrichten/Nier…
4
2
7
Check out the article from the local newspaper @Tagblatt tagblatt.de/Nachrichten/Ther…
3
1
We are starting a phase-I #clinicaltrial for our peptide #vaccine against chronic lymphocytic leukemia (CLL). The aim is to avoid relapse due to minimal residual disease after first line therapy with Ibrutinib. @uktuebingen medizin.uni-tuebingen.de/de/…
1
5
6
Können frühere Erkältungen gegen #Covid_19 schützen?🤔Das Forscherteam um Dr. @JulianeWalz zeigt, wie das #Immunsystem aus bereits überstandenen Infektionen lernt und sich anpasst. #uniklinikumtuebingen #Coronavirus #TZellen # @LabWalz
3sat@3sat20 Nov 2020
Können frühere Erkältungen gegen Covid schützen? Ganz abwegig ist die Idee nicht 👇 kurz.3sat.de/nt3S1/#xtor=CS1… #3satWissen💡 #Coronaviren #Immunsystem
1
6
7
Check out this short german TV coverage on our #SARS_CoV_2 peptide #vaccine by @3sat 3sat.de/wissen/nano/201214-p…
4
7
Very happy and excited that one of our publications is among the 5 most popular scientific papers in the Nature Index journals #sciencetwitter #SARS_CoV_2
This Post is from a suspended account. Learn more
5
5
Check out our latest review "The peptide #vaccine of the future" by @AnnikaNel published in @molcellprot mcponline.org/content/mcprot… mcponline.org/content/early/…
5
1
5
Check out the online preprint on our work defining #SARSCoV2 T-cell epitopes SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition researchsquare.com/article/r…
1
3
8
Load more